From: New discoveries on the biology and detection of human chorionic gonadotropin
Source | n | Total hCG mIU/ml median (range) | hCG-H mIU/ml molar1 % total hCG ± SD? | HhCGβ mIU/ml molar1 % total hCG ± SD |
---|---|---|---|---|
Complete hydatidiform mole (prior to evacuation) | 30 | 192,995 (24160 – 3704084) | 4.9 ± 2.1% | 7.1 ± 20%3 |
Partial hydatidiform mole (prior to evacuation) | 21 | 48,900 (11600 – 220114) | 3.6 ± 1.7% | 5.8 ± 22%3 |
Invasive mole, recurrent mole (at commencement of therapy) | 72 | 869 (24 – 30255) | 30 ± 35% | 7.7 ± 11% |
PSTT (at time of diagnosis)2 | 21 | 30 (1 – 231) | 7.1 ± 13% | 61 ± 21% |
Highly invasive Choriocarcinoma > 50% hyperglycosylated hCG2 | 17 | 45,350 (3,020 – 596,600) | 98 ± 5% | 7.8 ± 8.4% |
Invasive Choriocarcionoma < 50% hyperglycosylated hCG | 44 | 4,258 (108 – 10,245) | 32 ± 11% | 6.4 ± 7.5% |
Quiescent GTD (at time of diagnosis)2 | 93 | 22 (1 – 212) | 0.10% ± 0.72% | 2.7 ± 8.4% |
Other gynecologic malignancies (at time of diagnosis)2 | 14 | 33 (0.5 – 474) | 0.55 ± 1.3% | 91 ± 11% |